Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A7.

Figure A7

Vaccine efficacy (VE) for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 60 years) with low respiratory tract disease (LRTD) with 2 or signs/symptoms (I2 82.5%, 95% CI 55.0 to 93.2; tau2 0.675, 95% CI 0.122 to 11.471; Q = 17.14, p < 0.001) [51,52,82,83].